346 related articles for article (PubMed ID: 20457278)
41. Renal acute cellular rejection: correlation between the immunophenotype and cytokine expression of the inflammatory cells in acute glomerulitis, arterial intimitis, and tubulointerstitial nephritis.
Sementilli A; Franco M
Transplant Proc; 2010 Jun; 42(5):1671-6. PubMed ID: 20620497
[TBL] [Abstract][Full Text] [Related]
42. Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis.
Foell D; Hernández-Rodríguez J; Sánchez M; Vogl T; Cid MC; Roth J
J Pathol; 2004 Nov; 204(3):311-6. PubMed ID: 15476267
[TBL] [Abstract][Full Text] [Related]
43. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines.
Kalinina N; Agrotis A; Antropova Y; DiVitto G; Kanellakis P; Kostolias G; Ilyinskaya O; Tararak E; Bobik A
Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2320-5. PubMed ID: 15374849
[TBL] [Abstract][Full Text] [Related]
44. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.
Hernández-Rodríguez J; Segarra M; Vilardell C; Sánchez M; García-Martínez A; Esteban MJ; Queralt C; Grau JM; Urbano-Márquez A; Palacín A; Colomer D; Cid MC
Rheumatology (Oxford); 2004 Mar; 43(3):294-301. PubMed ID: 14679293
[TBL] [Abstract][Full Text] [Related]
45. Tissue-destructive macrophages in giant cell arteritis.
Rittner HL; Kaiser M; Brack A; Szweda LI; Goronzy JJ; Weyand CM
Circ Res; 1999 May; 84(9):1050-8. PubMed ID: 10325242
[TBL] [Abstract][Full Text] [Related]
46. [From pathogenesis of giant cell arteritis to new therapeutic targets].
Samson M; Bonnotte B
Rev Med Interne; 2017 Oct; 38(10):670-678. PubMed ID: 28800947
[TBL] [Abstract][Full Text] [Related]
47. Pathogenic principles in giant cell arteritis.
Weyand CM; Goronzy JJ
Int J Cardiol; 2000 Aug; 75 Suppl 1():S9-S15; discussion S17-9. PubMed ID: 10980331
[TBL] [Abstract][Full Text] [Related]
48. Giant cell arteritis as an antigen-driven disease.
Weyand CM; Goronzy JJ
Rheum Dis Clin North Am; 1995 Nov; 21(4):1027-39. PubMed ID: 8592735
[TBL] [Abstract][Full Text] [Related]
49. Stereological study of neovascularization in temporal arteritis.
Nordborg C; Larsson K; Nordborg E
J Rheumatol; 2006 Oct; 33(10):2020-5. PubMed ID: 16924688
[TBL] [Abstract][Full Text] [Related]
50. The pathogenesis of giant cell arteritis: morphological aspects.
Nordborg C; Nordborg E; Petursdottir V
Clin Exp Rheumatol; 2000; 18(4 Suppl 20):S18-21. PubMed ID: 10948752
[TBL] [Abstract][Full Text] [Related]
51. Can immunocompetent cells and their cytokines play a role in atherogenesis?
Hansson GK; Stemme S; Geng YJ; Holm J
Nouv Rev Fr Hematol (1978); 1992; 34 Suppl():S43-6. PubMed ID: 1340528
[TBL] [Abstract][Full Text] [Related]
52. MMP (Matrix Metalloprotease)-9-Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis.
Watanabe R; Maeda T; Zhang H; Berry GJ; Zeisbrich M; Brockett R; Greenstein AE; Tian L; Goronzy JJ; Weyand CM
Circ Res; 2018 Aug; 123(6):700-715. PubMed ID: 29970365
[TBL] [Abstract][Full Text] [Related]
53. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation.
Kofler S; Nickel T; Weis M
Clin Sci (Lond); 2005 Mar; 108(3):205-13. PubMed ID: 15540988
[TBL] [Abstract][Full Text] [Related]
54. The role of toll like receptors in giant cell arteritis.
O'Neill L; Molloy ES
Rheumatology (Oxford); 2016 Nov; 55(11):1921-1931. PubMed ID: 26893518
[TBL] [Abstract][Full Text] [Related]
55. The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease.
Weyand CM; Berry GJ; Goronzy JJ
J Leukoc Biol; 2018 Mar; 103(3):565-575. PubMed ID: 28848042
[TBL] [Abstract][Full Text] [Related]
56. An immunohistochemical analysis of fibroblasts in giant cell arteritis.
Parreau S; Vedrenne N; Regent A; Richard L; Sindou P; Mouthon L; Fauchais AL; Jauberteau MO; Ly KH
Ann Diagn Pathol; 2021 Jun; 52():151728. PubMed ID: 33798926
[TBL] [Abstract][Full Text] [Related]
57. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis.
Corbera-Bellalta M; Alba-Rovira R; Muralidharan S; Espígol-Frigolé G; Ríos-Garcés R; Marco-Hernández J; Denuc A; Kamberovic F; Pérez-Galán P; Joseph A; D'Andrea A; Bondensgaard K; Cid MC; Paolini JF
Ann Rheum Dis; 2022 Apr; 81(4):524-536. PubMed ID: 35045965
[TBL] [Abstract][Full Text] [Related]
58. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis.
Ma-Krupa W; Jeon MS; Spoerl S; Tedder TF; Goronzy JJ; Weyand CM
J Exp Med; 2004 Jan; 199(2):173-83. PubMed ID: 14734523
[TBL] [Abstract][Full Text] [Related]
59. Arterial wall fibrosis in Takayasu arteritis and its potential for therapeutic modulation.
Misra DP; Singh K; Sharma A; Agarwal V
Front Immunol; 2023; 14():1174249. PubMed ID: 37256147
[TBL] [Abstract][Full Text] [Related]
60. Immune checkpoint dysfunction in large and medium vessel vasculitis.
Watanabe R; Zhang H; Berry G; Goronzy JJ; Weyand CM
Am J Physiol Heart Circ Physiol; 2017 May; 312(5):H1052-H1059. PubMed ID: 28314758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
